End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.41 CNY | -1.04% | +1.43% | -19.42% |
Apr. 25 | Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 18 | Huadong Medicine's 2023 Profit Jumps 14% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.42% | 8.09B | B- | ||
+20.94% | 72.78B | C+ | ||
-1.26% | 24.24B | C+ | ||
+5.13% | 8.59B | C | ||
+8.25% | 8.38B | B | ||
+5.56% | 4.81B | B- | ||
+16.83% | 4.32B | B+ | ||
-1.83% | 4.05B | B- | ||
+26.97% | 3.79B | C+ | ||
+7.59% | 3.34B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000963 Stock
- Ratings Huadong Medicine Co., Ltd